StackTerminal.Health

BETA
Alternative layoutGrade B · 84Clean

Peptide Recovery Stack (BPC-157 + TB-500)

BPC-157 & TB-500 are the two most researched recovery peptides, with complementary mechanisms. BPC-157 (Body Protection Compound) accelerates tendon, ligament, & gut repair via angiogenesis & growth factor upregulation. TB-500 (Thymosin Beta-4) promotes systemic tissue repair, reduces inflammation, & improves mobility. GHK-Cu supports collagen synthesis & skin regeneration. Note: all three are research compounds not approved for human therapeutic use.

What this is for
General support
recovery, peptides, tissue-repair
Why you are seeing this
Goal fit: recovery, peptides, tissue-repair.
What to do next
Add body metrics if you want dose previews to reflect your weight rather than the reference dose.
PublicBuilt 08 Apr 20263 ingredientsNo interactions detected
Core stack
The main ingredients doing the work.
3 key items
2× weekly subcutaneous • Injectable
Promotes tendon-to-bone healing, gut mucosal repair, & angiogenesis via VEGFR2 & growth hormone receptor upregulation.
0mg
Safety / pharmacokinetics
Low
Population: Healthy volunteers
Study type: Registered phase 1 trial (results not posted)
Dose context: • Duration: See registry

A phase 1 safety/PK study in healthy volunteers was registered; results were not posted & the submission was canceled per later reviews, limiting interpretability.

Citation: ClinicalTrials.gov NCT02637284 — PCO-02 Safety and Pharmacokinetics Trialhttps://clinicaltrials.gov/study/NCT02637284
Musculoskeletal healing (preclinical)
Low
Population: Animal injury models (multiple tissues)
Study type: Narrative review of preclinical evidence
Dose context:

Across animal models, BPC-157 is frequently reported to improve healing-related outcomes (tendon/ligament/muscle/bone & GI injury models), but translation to humans remains unproven.

Citation: Vasireddi et al., (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine (review)https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
Soft tissue healing signals (preclinical)
Low
Population: Animal models (multiple tissues)
Study type: Review (preclinical-focused)
Dose context:

Multiple preclinical models report improvements in healing-related endpoints; translation to humans remains unproven.

Citation: Cushman et al., Local and Systemic Peptide Therapies for Soft Tissue Healing (2024)https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/
2× weekly subcutaneous • Injectable
Systemic tissue repair & anti-inflammatory via actin-binding, promoting cell migration & reducing fibrosis.
5mg
Wound healing
Low
Population: Rat full-thickness wound model
Study type: Preclinical animal study
Dose context:

TB4 accelerated wound healing endpoints in a rat model compared with controls.

Citation: Malinda et al., J Invest Dermatol (1999)DOI: 10.1046/j.1523-1747.1999.00708.xhttps://pubmed.ncbi.nlm.nih.gov/10469335/
Wound healing (clinical development)
Low
Population: Patients with venous stasis ulcers
Study type: Registered phase 2 trial (TB4 gel)
Dose context: • Duration: Up to 84 days (per registry)

TB4 gel has been studied in venous stasis ulcer indications; registry evidence supports clinical testing, though effect sizes depend on the specific trial & endpoint reporting.

Citation: ClinicalTrials.gov NCT00832091 — Thymosin Beta 4 in Venous Stasis Ulcershttps://clinicaltrials.gov/study/NCT00832091
Wound healing (reviewed clinical context)
Low
Population: Stasis and pressure ulcer clinical programs
Study type: Review article
Dose context:

A review summarizes phase 2 wound-healing programs reporting faster healing in those that did heal; note that these are not sports injury RCTs.

Citation: Treadwell et al., Ann N Y Acad Sci (2012) — The regenerative peptide thymosin β4 accelerates the rate of dermal healinghttps://pubmed.ncbi.nlm.nih.gov/23050815/
Daily topical or subcutaneous • Topical or injectable
Copper peptide that stimulates collagen & elastin synthesis, supporting skin regeneration & wound healing.
1mg
Extracellular matrix remodeling via MMP-2 upregulation
Low
Population: In vitro (human fibroblast cultures)
Study type: In vitro mechanistic study
Dose context: • Duration: Cell culture (acute exposure)

GHK-Cu significantly increased MMP-2 (matrix metalloproteinase-2) protein levels and corresponding mRNA in fibroblast culture media. TIMP-1 and TIMP-2 secretion also rose, indicating balanced matrix remodeling activity. The copper component was essential - GHK peptide alone produced no effect. Authors conclude GHK-Cu acts as both an activator of connective tissue production and a regulator of extracellular matrix remodeling.

Citation: Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-65.DOI: 10.1016/s0024-3205(00)00803-1https://pubmed.ncbi.nlm.nih.gov/11045606/
Grade is LOW because this is an in vitro study only - no human or animal data. Results are mechanistically plausible and consistent with GHK-Cu's known biology, but cannot be directly extrapolated to dosing or clinical outcomes.
Skin appearance / remodeling (summary of clinical + mechanistic evidence)
Moderate
Population: Humans (cosmetic/dermatologic contexts) + preclinical
Study type: Review
Dose context:

Review summarizes reported improvements in some skin measures & broad tissue-remodeling biology; quality & comparators vary widely. The authors note a surprising absence of rigorous modern clinical trials for GHK-Cu in anti-wrinkle applications despite widespread cosmetic use.

Citation: Pickart et al., Molecules (2018) — Regenerative and Protective Actions of the GHK-Cu PeptideDOI: 10.3390/ijms19071987https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
Wrinkle improvement (objective measures)
Low
Population: Adults using topical copper tripeptide complex
Study type: Clinical study (objective evaluation)
Dose context:

One objective evaluation reported no significant improvement in wrinkles/overall skin quality, though patient satisfaction differed; underscores mixed results across formulations & endpoints.

Citation: Miller et al., Arch Facial Plast Surg (2006) — Topical copper tripeptide complex evaluationDOI: 10.1001/archfaci.8.4.252https://www.liebertpub.com/abs/doi/10.1001/archfaci.8.4.252
Stack pre-check
No personal data connected — connect wearables or upload bloodwork for a personalised check
Clean
Supplements
3
Training load
Unknown
No flags
No duplication, stimulant, interaction, or recovery concerns detected.

Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.

Interaction Analysis
Pharmacokinetic + pair-level checks
Timing optimizations
BPC-157
Take ~1h before the intended effect window
Reaches peak plasma concentration in ~1h. Half-life ~4h.
TB500 (TB4 / Thymosin Beta-4)
Take ~1h before the intended effect window
Reaches peak plasma concentration in ~1h. Half-life ~4h.
GHK-Cu
Take ~15 min before the intended effect window
Reaches peak plasma concentration in ~15 min. Half-life ~0.5h.

Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.

Similar community stacks

If this is close but not quite right, start from a similar stack rather than from zero.

Browse all community stacks →
recoveryskinresearch-only

Adds a copper peptide often discussed in cosmetic/skin contexts to a recovery/joint pairing. Evidence is indirect & component-based.

BPC-157
1mg
TB500 (TB4 / Thymosin Beta-4)
1mg
GHK-Cu
1mg
New
View
strengthrecoverydaily

My Sample Stack

by@tin_man140_6

Built from your selected goals, constraints, diet, & the supplement evidence library. You can edit doses & timing.

Vitamin B-Complex
26mg
Vitamin C
500mg
Ashwagandha
600mg
+ 3 more supplements
New
View
strengthrecoverydaily

Built from your goals & the supplement evidence library. You can edit doses & timing.

Caffeine
200mg
Beta-Alanine
3200mg
Vitamin D3
50mg
+ 3 more supplements
New
View